Clinical trial
Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
NCT00261547 · Massachusetts General Hospital, Other · Withdrawn
Key facts
| NCT number | NCT00261547 |
|---|---|
| Title | Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients |
| Official title | Pilot Study of Rituximab Treatment to Inhibit HLA Antibodies in Renal Allograft Recipients |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Rejection, Kidney Insufficiency |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 0 |
| Start date | Dec 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Dec 5, 2005 |
| Last update posted | Oct 23, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: